Cardiogen is a research-only peptide bioregulator with no FDA-approved dosing. The pattern below is commonly cited in the community and anecdotal — it is not medically established, and the underlying evidence is thin. Amounts are not standardized across sources. This is educational context, not a protocol.
Overview
Cardiogen is one of the Khavinson-style "peptide bioregulators" marketed for tissue-specific support — here, cardiovascular tissue. The proposed tissue selectivity is a hypothesis, not a validated dose-response relationship, so there is no rigorously established amount.
Commonly cited dosing pattern
Bioregulators are usually discussed as short courses rather than continuous use. The generic pattern repeated across community sources is:
- Roughly ~10 mg per day is the commonly cited figure, though sources vary and it is not standardized.
- Given in short cycles of about 10–20 days, then a break.
- Some users repeat a cycle a few times per year.
Treat these as anecdotal reference points, not a validated regimen. Because the evidence base is thin, a cautious approach is to start at the low end and only under supervision, if at all.
How it is administered
Cardiogen is sold either as a lyophilized peptide for reconstitution and subcutaneous injection, or as an oral capsule form.
- For injectable material, mass divided by diluent volume sets concentration — see the Peptide Calculator.
- Dose is read as syringe units of volume, an error-prone conversion.
- Pharmacokinetics of very short peptides are poorly characterized, so exposure over time is uncertain.
Why oversight matters
Cardiogen has no regulator-approved indication, no defined contraindications or monitoring, and no dedicated dosing trials — and cardiovascular health in particular warrants real medical care. Research-grade purity is not guaranteed. A qualified clinician can weigh your health context before anything is done at all. The figures above reflect online convention, not evidence.